Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 212 | 24 | 173 |
| Samples | 204 | 21 | 171 |
| Peptides | 162 | 22 | 140 |
Function
ARPC4-TTLL3 · ARPC4-TTLL3 readthrough
This locus represents naturally occurring read-through transcription between the neighboring ARPC4 (actin related protein 2/3 complex, subunit 4) and TTLL3 (tubulin tyrosine ligase-like family, member 3) genes. The read-through transcript encodes a fusion protein that shares sequence identity with each individual gene product. [provided by RefSeq, Nov 2010].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000397256 | P59998-2 | 212 | 162 |
Gene Properties
Recurrent Mutations
All 170 amino-acid changes on canonical ENST00000397256 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ARPC4-TTLL3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ARPC4-TTLL3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 15/612 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 12/810 1% |
| Gastric Carcinoma | 0/74 0% | 25/1809 1% |
| Colorectal Carcinoma | 5/143 4% | 34/3239 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Melanoma | 3/210 1% | 18/1899 1% |
| Bladder Carcinoma | 0/58 0% | 10/956 1% |
| Burkitts Lymphoma | 0/32 0% | 2/196 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 9/1390 1% |
| Neuroendocrine Tumour | 1/154 1% | 3/577 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Other Solid Cancers | 1/94 1% | 5/1515 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Hepatocellular Carcinoma | 1/46 2% | 5/2210 0% |
| Ovarian Carcinoma | 0/109 0% | 3/998 0% |
| Breast Carcinoma | 1/144 1% | 7/3264 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 3/1592 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 4/2534 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Prostate Carcinoma | 1/13 8% | 2/2105 0% |
| Glioma | 0/52 0% | 3/2127 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
Mutation Distribution
Where ARPC4-TTLL3 is mutated · all tissues, split by cell line vs tissue
How many mutations in ARPC4-TTLL3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 212 mutations in ARPC4-TTLL3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|